Physician profile
Stephen R Patton
NPI 1093700692
$789.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $253.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $168.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $131.01 | 2019-2020 | |
| Vifor Pharma, INC. | $108.90 | 2019 | |
| Amgen INC. | $77.28 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $67.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $58.10 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $55.58 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $52.94 | 2019 | |
| Daiichi Sankyo INC. | $40.21 | 2020 | |
| Amag Pharmaceuticals, INC. | $18.13 | 2019 | |
| Novo Nordisk INC | $11.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.